Event in Progress:
Discover the latest content that has just been published on Research Tree
Sika has published better than expected Q1 21 results with double-digit organic growth observed in all segments. The performance was particularly strong in the Americas, which benefited from volume growth driven by large-scale refurbishment and new-build projects in connection with distribution and data centres. The company has confirmed its 2023 strategic targets, but we believe that the organic growth in 2022 will be beyond the 10% guided by the company.
Companies: Sika AG
AlphaValue
Sika published a good set of FY21 results, but slightly below our expectations. It registered sales growth across all markets, and slightly above our estimates, but the EBIT margin was shy by 60bp and net profit by 2%. Management proposed a dividend of CHF2.9, in line with our estimate.
After successfully closing the integration of the Parex business, Sika has announced its next big acquisition. Valued at €5.2bn, MBCC will be Sika’s largest acquisition to date. The purchase price represents an 11.5x EV/pro forma 2022E EBITDA, which is a cheap buy for Sika which trades at 21.9x EV/EBITDA. The transaction will be highly complementary across nearly all of Sika’s core technologies, applications and solutions and will bring Sika’s sales to nearly CHF13bn by 2023 (vs CHF9.4bn in 2021
Sika published a good set of 9m results with sales up by 18.1% in local currencies and 18.2% in CHF. The America region, China and India continue to show strong demand momentum but the same cannot be said for the EMEA region. The Global segment too is suffering from the semiconductor shortage but Sika was able to manage its top-line figures via frequent price increases and the EBIT by better cost management.
Sika published better than expected H1 results with a positive sales growth observed across all segments. Sales growth in Europe, due to the strong residential renovation trend, came as a surprise, while the strong rally in APAC was expected. Following the good set of result, the company has updated its FY21 guidance. We too have revised our estimates upwards, but it did not have a significant impact on the target price.
Sika has published better than expected Q1 20 results with organic growth observed in all segments. Once again Sika’s acquisition of Parex turned out to be fruitful, being visible by the double-digit organic growth observed in China. Following the strong performance, especially in Europe and APAC, the company has raised its full-year targets. We have revised our numbers upwards.
Thomas Hasler will succeed Paul Schuler as the CEO from May 2021 and, therefore, FY20 was the last full year in the current CEO’s reign. The FY20 results were a good farewell present to him, with growth in all regions despite the pandemic, a significant increase in the EBIT margin, and successful completion of the integration of Parex, which was the biggest acquisition carried out by him. Sika has proposed a dividend of CHF2.5/share and re-confirmed its 2023 strategic targets.
Sika has released preliminary FY20 figures with a growth of 3.4% registered in local currency but strongly dragged down by negative FX (-6.3%). The company, however, outperformed the market expectations by announcing stronger margins (Sika expects the EBIT margin to be ~14% vs AV est. of 13.3% and consensus 13.5%).
Sika has published a good set of 9m results with sales up by 2.6% in local currencies. However, it saw a strongly negative currency effect of –6.0%, resulting in an actual sales decline of -3.4%. The best performer was the APAC region which posted growth of 13.9% in local currencies and 8.3% in CHF and the improvement in Global Business was a positive surprise. For FY20, management has provided guidance of lower sales but an EBIT in line with FY19 figures.
Companies: SIKAN 0Z4C SIKA SIKA SKFOF
Sika published its H1 results which were better than our expectations with a positive sales growth of +2.9% in local currencies supported by the acquisition effect of +13.4%. The EBITDA margin was almost flat. For H2, management is confident of seeing positive organic growth. The 2023 strategic targets are still intact. We will be revising our numbers upwards.
Sika has demonstrated strong growth of 15.4% in sales in Q1 20. This growth was backed by increased pricing, the acquisition effect of Parex, and the late impact of COVID-19 in the Americas and Europe. The company is implementing significant cost-saving methods to deal with the current situation, yet it has dropped its 2020 guidance pertaining to the uncertainties. The 2023 guidance is still intact. Our minor tweaks in the model following this release do not change our recommendation.
The FY19 results were in line with our expectations and the company has reiterated its 2023 targets. Management is confident about 2020 despite the Coronavirus fears in China, and believes that it will be able to achieve 10% growth 2020. It has further confirmed that a big M&A is a possibility as the Parex integration is almost over.
The group has announced its FY19 sales up 14.4%, with organic growth contributing only 3.3%. All regions showed growth with APAC being the strongest. Through five acquisitions, the group has laid the foundations for continued growth. It has set Strategy 2023 where it seeks to grow by 6-8% each year upto 2023. It is also aiming a higher EBIT margin of 15-18% in 2021 while, according to our estimation, it was ~13% in 2019.
Following this earnings release, we will increase our sales forecast and leave unchanged the margin accretion. This will result in a higher target price by some 5-12% depending on our other changes in assumptions.
Sika registered a solid H1 19 but this was mainly thanks to acquisitions as the organic growth was at its lowest level over the last three H1s, with +3.1% vs +6.8% in H1 18 and +5.7% in H1 17. But the disappointing fact is the change in wording about the guidance, which is somewhat a negative. Overall, we will increase the target price by 5-10% in order to switch back to a Buy recommendation, as Sika remains our top pick.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Sika AG. We currently have 1 research reports from 3 professional analysts.
Strix has reported FY23 results to 31 December 2023 with adjusted PAT of £20.1m, in line with our updated forecast and company guidance provided in January. Revenue grew 35.2% to £144.6m, benefitting from the full year inclusion of the Billi acquisition, albeit slightly below our forecast of £151.0m. Its core Kettle Controls division also performed robustly, growing 2.7%, ahead of the broader market and indicating market share gain. Recent acquisitions have noticeably improved the Group’s growth
Companies: Strix Group PLC
Zeus Capital
Companies: Yu Group PLC
Liberum
Companies: FOG PEB KBT EMR TIME GETB JNEO
Cavendish
Cohort announces that its subsidiary SEA (Systems Engineering and Assessment Ltd.) has been awarded a major contract by the UK’s Ministry of Defence to provide Electronic Warfare Counter Measures (Increment 1a) (EWCM 1a) to the Royal Navy with a total value of at least £135m. This includes provision and support of SEA’s Trainable Decoy Launcher System, Ancilia. At the FY 24 interim results Cohort had commented on an overall “increased tempo” of order intake. The Group reported a closing order b
Companies: Cohort plc
Equity Development
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
Companies: Luceco PLC
Positives emerged, particularly in H2, as the recovery commenced within the kettle controls market. Billi was the architect of the revenue improvement, with LAICA also delivering a double-digit increase in the top line. Margins improved, notwithstanding a change in the mix. Encouragingly, investor concerns on debt were allayed with the careful management of cash, and latterly as bankers raised the net debt/EBITDA covenant to 2.75x. With further emphasis on costs and cash conservation and a lik
Quadrise continues to advance towards commercial revenues for its innovative fuel and biofuel technologies, with each of its projects approaching key milestones in 2024. Preparatory steps for the MSC Shipmanagement (MSC) fuel trials are now complete and fuel supply agreements are nearing finalisation. Quadrise will achieve its first licensing revenues on the successful completion of Valkor’s project financing (timing uncertain). Quadrise also successfully concluded its Morocco trial, paving the
Companies: Quadrise PLC
Edison
Companies: FOG TND BVXP ACC HDD
Companies: Michelmersh Brick Holdings PLC
Canaccord Genuity
Companies: Flowtech Fluidpower plc
Judges Scientific is a group involved in the buy and build of scientific instrumentation businesses. Testament to the strength of its highly engineered offer and global diversified customer base, total revenue increased an impressive 20.2% to £136.1m (organic +15%), with adj. PBT +7.5% to £31.7m (FY2022: £28.3m), 3.1% ahead of our estimate of £30.5m. Fully diluted (FD) adjusted EPS increased a more muted 2.6% (impacted by anticipated tax headwinds) to 368.5p (basic adj EPS 374.5p), 3.4% ahead of
Companies: Judges Scientific plc
WHIreland
Companies: BILN IGP RBN SBTX
Gelion has reported in line H1 FY24 results that demonstrate continued strong cash management and steady progress in its pursuit of next generation lithium-sulphur battery technologies. Encouraging early test results justify last year’s IP acquisitions and validate Gelion’s Li-S battery technology plan, with additional progress expected to be reported in H2 alongside its pursuit of a strategic partner for its planned Advanced Commercial Prototyping Centre (ACPC) facility in Australia. There is a
Companies: Gelion PLC
Forterra’s FY23 (to 31 December) earnings were slightly higher than guidance, which was raised in January, with resilient pricing partly offsetting a steep fall in demand among its main end users, large housebuilders. Our estimates are broadly unchanged, other than reflecting a more conservative stance on the final dividend. Despite a cautious tone in the outlook statement, we believe the largest housebuilders may now rebound more strongly than smaller peers.
Companies: Forterra Plc
Progressive Equity Research
Share: